Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIGHT-302
2024-513513-12-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of pemigatinib in cholangiocarcinoma (CCA) (2 arms), sponsored by Incyte. Primary endpoint: Progression-free survival. Started Aug 2024; status: completed.
02
Drugs
pemigatinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on 2024-513513-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513513-12-00.